Olema Pharmaceuticals (OLMA) Interest & Investment Income (2020 - 2026)
Olema Pharmaceuticals' (OLMA) quarterly Interest & Investment Income came in at $4.8 million in Q1 2026, up 5.57% year-on-year from $4.5 million in Q1 2025, and up 19.1% on a QoQ basis from $4.0 million in Q4 2025.
Olema Pharmaceuticals (OLMA) Interest & Investment Income (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has 7 years of Interest & Investment Income data on file, last reported at $4.8 million in Q1 2026.
- On a quarterly basis, Interest & Investment Income rose 5.57% year-over-year to $4.8 million in Q1 2026; TTM through Mar 2026 was $16.5 million, a 18.93% increase from a year earlier, with the FY2025 full-year figure at $16.2 million, up 27.93% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $4.8 million, up from $4.0 million in the prior quarter.
- Over the last five years, Interest & Investment Income for OLMA reached as high as $4.8 million in Q1 2026 and fell as low as $218000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $2.6 million across 5 years, with a median of $3.1 million in 2024.
- Across the five-year window, Interest & Investment Income soared 792.66% in 2022 and retreated 7.24% in 2024, its largest moves.
- Year by year, Interest & Investment Income stood at $973000.0 in 2022, then surged by 264.95% to $3.6 million in 2023, then declined by 7.24% to $3.3 million in 2024, then climbed by 21.74% to $4.0 million in 2025, then grew by 19.1% to $4.8 million in 2026.
- Per Business Quant data, the three most recent Interest & Investment Income figures were $4.8 million in Q1 2026, $4.0 million in Q4 2025, and $3.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Olema Pharmaceuticals | 1.26 Bn | 1.26 Bn | - | 4.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.78 Mn |
| Dec 31, 2025 | 4.01 Mn |
| Sep 30, 2025 | 3.65 Mn |
| Jun 30, 2025 | 4.04 Mn |
| Mar 31, 2025 | 4.52 Mn |
| Dec 31, 2024 | 3.29 Mn |
| Sep 30, 2024 | 2.93 Mn |
| Jun 30, 2024 | 3.11 Mn |
| Mar 31, 2024 | 3.35 Mn |
| Dec 31, 2023 | 3.55 Mn |
| Sep 30, 2023 | 1.92 Mn |
| Jun 30, 2023 | 1.55 Mn |
| Mar 31, 2023 | 1.31 Mn |
| Dec 31, 2022 | 973,000.00 |
| Sep 30, 2022 | 622,000.00 |
| Jun 30, 2022 | 415,000.00 |
| Mar 31, 2022 | 218,000.00 |
| Dec 31, 2021 | 109,000.00 |
| Sep 30, 2021 | 105,000.00 |
| Jun 30, 2021 | 117,000.00 |